| 21.08 -1.11 (-5%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 37.57 |
1-year : | 45.83 |
| Resists | First : | 32.17 |
Second : | 39.24 |
| Pivot price | 26.66 |
|||
| Supports | First : | 20.73 |
Second : | 17.25 |
| MAs | MA(5) : | 22.27 |
MA(20) : | 29.08 |
| MA(100) : | 43.37 |
MA(250) : | 49.85 |
|
| MACD | MACD : | -5.1 |
Signal : | -4.8 |
| %K %D | K(14,3) : | 2.8  |
D(3) : | 2.1 |
| RSI | RSI(14): 12 |
|||
| 52-week | High : | 94.9 | Low : | 20.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GPCR ] has closed above bottom band by 15.0%. Bollinger Bands are 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 22.16 - 22.29 | 22.29 - 22.39 |
| Low: | 20.37 - 20.54 | 20.54 - 20.68 |
| Close: | 20.83 - 21.08 | 21.08 - 21.29 |
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Thu, 01 Oct 2026
Structure Therapeutics (NasdaqGM:GPCR) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 22 Sep 2026
Structure Therapeutics (GPCR) CMO sells shares under preset plan - Stock Titan
Tue, 22 Sep 2026
Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus - Yahoo Finance
Mon, 21 Sep 2026
Planned $140K share sale by Structure Therapeutics (Nasdaq: GPCR) officer - Stock Titan
Tue, 08 Sep 2026
Structure Therapeutics falls on obesity drug data (GPCR:NASDAQ) - Seeking Alpha
Mon, 24 Aug 2026
Structure Therapeutics (GPCR): Can Upcoming Obesity Trial Catalysts Help Regain Its Form? - RTTNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 97.6 (%) |
| Shares Short | 7,540 (K) |
| Shares Short P.Month | 5,850 (K) |
| EPS | -3.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15 % |
| Return on Equity (ttm) | -20.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -220 (M) |
| Levered Free Cash Flow | -119 (M) |
| PE Ratio | -6.96 |
| PEG Ratio | 0 |
| Price to Book value | 1.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|